Mylan Cautiously Optimistic About India Market Following Approval Of Agila Acquisition
This article was originally published in PharmAsia News
Executive Summary
The global generics giant hopes to take a quantum leap in its business prospects. But Mylan remains cautious about striking business deals in India in the wake of changing pricing and policy dynamics.